Biologics

#Biologics #Cannabinoid #Cell programming

Partnership achieves equity milestone to produce cannabinoids 

Cronos Group and Ginkgo Bioworks have achieved the first target productivity milestone in their partnership to produce eight cultured cannabinoids.   Using Ginkgo’s platform for organism design and development, Cronos Group has successfully achieved the productivity target for cannabigerolic acid (CBGA), which will support Cronos Group’s planned CBG product launch this fall. … Read More

#News

#Biologics #Biology #Data #Genetics / genomics #RNA #Therapeutics

Starting line: focus on Canadian start-ups

DDW Editor Lu Rahman selects three Canadian start-ups worth watching: AbCellera Biologics, BlueRock Therapeutics and Deep Genomics. AbCellera Biologics AbCellera Biologics was founded in 2012 as a spin out from the University of British Colombia. The company searches, decodes, and analyses natural immune systems to find antibodies that can be… Read More

#Business & Investment #Editor's Choice #Exclusive Content #News #Opinion #Start-up Zone

#Biologics #Cancer research #Drug development #mRNA #R&D

What it means for drug discovery to partner with a CDMO

Following the announcement by Samsung Biologics that it planned to add mRNA vaccine drug substance manufacturing services to its offering, DDW’s Megan Thomas spoke to Seahee Kim about what this means for both business and drug development.   MT: As a CDMO, Samsung Biologics can offer both development and manufacturing services. Read More

#Business & Investment #Cancer Research #Editor's Choice #Exclusive Content #News

#AI / data analytics / healthtech / informatics #Biologics #Cell culture #Mass spectrometry / NMR

New data integrations to accelerate bioprocess data insights

908 Devices has announced two data analysis partnerships to integrate with the REBEL, its first at-line fresh and spent cell media analyser for bioprocess labs. With the integration of leading data exploratory tool Sartorius’ SIMCA and Securecell’s Lucullus Process Information Management System (PIMS), users can turn REBEL data into deeper… Read More

#News

#Biologics #Biopharmaceuticals #Drug delivery #Drug development #Events #Process analytical technology

Agilent completes the InfinityLab Bio LC portfolio

Agilent Technologies has launched three InfinityLab Bio LC systems specifically developed to meet the needs of the biopharma industry. The release has been described by Agilent as central to its portfolio of complete Bio LC solutions, featuring instruments, columns, and supplies that integrate with Agilent OpenLab and MassHunter software, and… Read More

#News

#Biologics #Cell and gene therapy #Drug development

Yposkesi launches construction of its second commercial bioproduction site

Yposkesi, a Contract Development and Manufacturing Organisation (CDMO) specialising in cell and gene therapies, has announced the launch of project SKY, the construction of Yposkesi’s second commercial cell and gene therapy facility and new global resource for drug developers of biologics, also called ATMPs (Advanced Therapy Medicinal Products). ATMPs treat… Read More

#News

#Biologics #Clinical trials #Crohn's disease

Study of biologic therapies for moderate to severe Crohn’s Disease

The Janssen Pharmaceutical Companies of Johnson & Johnson has released efficacy and safety data for STELARA (ustekinumab) in Crohn’s disease (CD) and ulcerative colitis (UC), including data from the SEAVUE study, the first study of biologic therapies in patients with CD, presented in a Clinical Science Late-Breaking Abstract Plenary session. Read More

#News

#Alzheimer's #Biologics

C. elegans: a natural model for developing therapies to slow ageing

Ageing is a complex and heterogeneous process and is best studied using natural models of ageing in whole organisms and large test populations. C. elegans is a proven model in many fields of biology including ageing, where major breakthroughs have occurred by identifying mutants and interventions that increase… Read More

#News #Videos

#Bioban #Biologics #Covid-19 #Life sciences #Thermo Fisher Scientific

Reforming biobanks: from siloes to collaborative powerhouses

By Erik Steinfelder, Biobanking Market Development Director at Thermo Fisher Scientific From hidden repositories, secreted deep in the basements of universities and hospitals, to the emergence of collaborative powerhouses driving ground-breaking therapies, biobanks have come a long way in the past 30 years. Biobanks were originally created as vast repositories… Read More

#Covid-19 #Exclusive Content #News

#Biologics #Cell / tissue culture #Covid-19 #Vaccines

Biden administration unblocks access to federal funded fetal tissue cells

A notice released by the US National Institutes of Health (NIH) on April 16, 2021 revealed that the Biden administration has reversed restrictions set in 2019 by the Trump administration on federal funding for medical research and biomedical studies by government employees using human fetal tissue from elective abortions. Health.com… Read More

#News

#Biologics #Covid-19 #Drug delivery #Gene therapy #Genetics / genomes #Immunology / Virology & Vaccines #RNA

The challenge of providing rapid, effective protection against Covid-19

Lisa Osborne, CEO at RANA Healthcare Solutions interviews Daniel Kavanagh, PhD, Senior Scientific Advisor, Gene Therapy at WCG. The Covid-19 pandemic has put vaccine development centre-stage. Never have citizens around the world been so focused on the length of time it takes to develop, test, approve, manufacture and distribute new… Read More

#Covid-19 #Exclusive Content #News

#Antibodies #Biologics #Covid-19 #Drug development #Drug discovery #Online focus

IONTAS has identified novel SARS-CoV-2 neutralising antibodies

IONTAS and FairJourney Biologics have identified neutralising antibodies, which bind to multiple emerging SARS-CoV-2 variants. The results, generated from a combination of phage display technology and B-cell receptor repertoire sequencing of hospitalised COVID-19 patients, identified potent neutralising antibodies with distinct mechanisms of action. Based on this approach, the company has… Read More

#News

#Antibodies #Biologics #Biologics / Biotechnology #Cell therapy

IONTAs and FairJourney antibody agreement with Quell Therapeutics

IONTAS and FairJourney Biologics (FJB) have entered into an agreement with Quell Therapeutics regarding IONTAS / FJB’s proprietary libraries and technology platforms. A diverse panel of novel target binders from IONTAS and FairJourney Biologics (FJB) will be used to identify antibodies to advance Quell’s engineered Treg cell therapy pipeline. Quell… Read More

#News #Trending News

#Biologics #Cancer immunotherapy #Oncology

Samsung Biologics obtains cancer immunotherapy IND approval from FDA

Samsung Biologics has obtained Investigational New Drug (IND) clearance from the FDA for its client to begin clinical trials on a cancer immunotherapy. In late 2018, National OncoVenture (NOV), a government-funded virtual oncology drug development program in Korea, approached Samsung Biologics for the development of EU101(NOV1801), an anti-4-1BB therapeutic monoclonal… Read More

#Cancer Research #News

#Antibody response #Biologics #Drug targets #Novel therapeutics #RNA #siRNA

Sitting down with…Michael Smyth, Galapagos UK

Michael Smyth is Medical Director at Galapagos UK, responsible for launching innovative therapies in the UK to help change the course of inflammatory disease for patients. Having studied medicine at Liverpool University, one of his personal missions is lifelong learning which is reflected in his role to strive for new treatment… Read More

#Editor's Choice #News #Opinion

#Biologics #Cell therapy

Solentim new standards in productivity with antibodies workflow solutions

Solentim, expert in cell therapy workflows enabling the creation, isolation and characterisation of high value cells, has launched two solutions to enhance the development of therapeutic antibodies. Icon is a benchtop system for the rapid stratification of high productivity clones and Studius is a proprietary software platform that delivers data… Read More

#News